Search filters

Filters

Clear All

Phase

  • 33
  • 94
  • 1
  • 80
  • 37
  • 1
  • 118
  • 386
  • 179
  • 13
  • 19
  • 354
  • 381
  • 5
  • 4
  • 382

Found 386 oncology trials

A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I Hormone Sensitive HER2-Negative Oncotype Recurrence Score 18 Breast Cancer (DEBRA* DE-escalation of Breast RAdiation)

All genders
Comparison of endocrine therapy alone (experimental arm) vs breast radiation and endocrine therapy (SOC) in hormone-sensitive, stage 1 breast cancer post lumpectomy. Oncotype Recurrence Score must be less than or equal to 18 in order to participate. The experimental arm will be tested for non-inferiority. HRQOL will be collected with …

API Push Not Cancer Study

All genders
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource utilization.

Study of the PKMYT1 Inhibitor RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors (MAGNETIC Study)

18 years - 99 years
All genders
Phase 1
Interventional
The purpose of this research study is to: • Test how safe RP-6306 and gemcitabine are when given together at different doses and on different schedules • Test how well RP-6306 and gemcitabine work together to shrink cancer in the body RP-6306 is a PKMYT1 inhibitor that is designed to …
 Evaluation of Vascular Health Profile in Predicting Venous Thromboembolism

Evaluation of Vascular Health Profile in Predicting Venous Thromboembolism

1 years - 99 years
All genders
The main goal of this study is to utilize previously validated cytometric markers of to identify cancer patients at high risk of VTE. The primary outcome will be DVT or pulmonary embolism (PE). Patients with pancreatic and brain cancer will be enrolled as these patients are known to have higher …
 METAMORPH

METAMORPH

All genders
This is a cohort study of women with suspected or confirmed recurrent breast cancer, with accessible tumor by standard clinical biopsy, prior to starting a new therapy for recurrent metastatic disease. Study participants will be ascertained from the population of all persons greater than eighteen years of age receiving care …
 Evaluating in vivo PARP-1 expression with 18F-FluorThanatrace positron emission tomography (PET/CT) in Pancreatic Cancer

Evaluating in vivo PARP-1 expression with 18F-FluorThanatrace positron emission tomography (PET/CT) in Pancreatic Cancer

All genders
Phase 1
This is a pilot study in patients with histologically proven pancreatic adenocarcinoma who have demonstrated at least stable disease following at least 16 weeks of treatment with platinum-based chemotherapy and are recommended for treatment with a PARP inhibitor with or without additional agents, either as part of their clinical care …

Prevention Employing a Multiomics Plasma-based Test for Colorectal Cancer

45 years - 85 years
All genders
Observational
The main goal of this research study is to collect health information and blood samples from people who are going to have a standard-of-care screening colonoscopy. The blood samples along with other health information from patients who take part in the study may help the Sponsor develop new diagnostic tests …
 Genetics and Heart Health after Cancer Therapy

Genetics and Heart Health after Cancer Therapy

All genders
The overall objective of this study is to use patient-centered in vitro and in vivo models to answer the fundamental question of whether or not pathogenic mutations in BRCA1/2 result in an increased risk of CV disease. We plan to enroll 100 BRCA1/2 mutation carriers who have been treated for …
 FES PET/CT in Endocrine Refractory Breast Cancer

FES PET/CT in Endocrine Refractory Breast Cancer

18 years - 99 years
All genders
Patients with recurrent or metastatic ER+ breast cancer, who have failed prior endocrine therapy may be eligible for this study.  Patients may participate in this study, if they are at least 18 years of age, most participants will be receiving care at the clinical practices of the University of Pennsylvania. …